{"article_title": "Bristol-Myers Revenue Improves on Cancer-Drug Sales", "article_keywords": ["cancerdrug", "shown", "used", "cancer", "revenue", "trials", "rise", "sales", "improves", "treatment", "watched", "squibb", "bristolmyers", "therapies"], "article_url": "http://www.wsj.com/articles/SB10001424052702304632204579340401570440272", "article_text": "Bristol-Myers Squibb Co. reported a better-than-expected 6% rise in fourth-quarter revenue and a 9% rise in adjusted earnings, benefiting from a portfolio of cancer therapies the company said it was aiming to expand.\n\nBristol said it would be conducting four clinical trials this year of its closely watched experimental cancer treatment nivolumab that could be used to apply for regulatory approval for lung cancer if the drug is shown...", "article_metadata": {"article.template": "snippet", "article.created": "2014-01-24T13:14:00.000Z", "article.section": "Business", "page.region": "na,us", "page.content.type": "Article", "twitter": {"domain": "wsj.com", "description": "Bristol-Myers Squibb Co. reported a better-than-expected rise in fourth-quarter revenue and improved adjusted earnings, benefiting from a portfolio of cancer therapies the company said it was aiming to expand.", "title": "Bristol-Myers Revenue Improves on Cancer-Drug Sales", "image": {"alt": "Bristol-Myers reports better-than-expected results, helped by cancer drug sales. $BMY", "identifier": "http://si.wsj.net/img/WSJ_Logo_black_social.gif"}, "site": "@WSJ", "card": "summary"}, "al": {"ios": {"url": "wsj://launch?articleid=SB10001424052702304632204579340401570440272&headline=Bristol-Myers%20reports%20better-than-expected%20results%2C%20helped%20by%20cancer%20drug%20sales.%20%24BMY&weburl=http://www.wsj.com/articles/SB10001424052702304632204579340401570440272"}}, "page.site.product": "WSJ", "keywords": "bristol cancer treatments,bristol earnings,bristol-myers,earnings,earnings season,fourth quarter,orencia,sprycel,Bristol-Myers%20Squibb,BMY,Pfizer,PFE,AstraZeneca,AZN.LN,AZN,Lamberto Andreotti,performance,earnings projections,analyst comments,recommendations,new products,services,corporate,industrial news,official trials,tests,cancer,political,general news,cancer research,health,medical conditions,pharmaceuticals,health care,life sciences", "news_keywords": "bristol cancer treatments,bristol earnings,bristol-myers,earnings,earnings season,fourth quarter,orencia,sprycel,Bristol-Myers%20Squibb,BMY", "article.headline": "Bristol-Myers reports better-than-expected results, helped by cancer drug sales. $BMY", "description": "Bristol-Myers Squibb Co. reported a better-than-expected rise in fourth-quarter revenue and improved adjusted earnings, benefiting from a portfolio of cancer therapies the company said it was aiming to expand.", "apple-itunes-app": "app-id=364387007,app-argument=wsj://launch?articleid=SB10001424052702304632204579340401570440272&headline=Bristol-Myers%20reports%20better-than-expected%20results%2C%20helped%20by%20cancer%20drug%20sales.%20%24BMY&weburl=http://www.wsj.com/articles/SB10001424052702304632204579340401570440272", "user.type": "nonsubscriber", "testkeys": "C", "article.page": "Business", "article.summary": "Bristol-Myers Squibb Co. reported a better-than-expected rise in fourth-quarter revenue and improved adjusted earnings, benefiting from a portfolio of cancer therapies the company said it was aiming to expand.", "page.site": "wsj", "page.content.format": "responsive", "article.published": "2014-01-24T18:07:00.000Z", "dj.asn": "i-79ec", "robots": "noarchive,noodp", "fb": {"app_id": 368513495882}, "article": {"internal_link_count": 1, "word_count": 469, "publisher": "https://www.facebook.com/wsj"}, "viewport": "width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no", "page.section": "Article", "language": "en-US", "og": {"site_name": "WSJ", "description": "Bristol-Myers Squibb Co. reported a better-than-expected rise in fourth-quarter revenue and improved adjusted earnings, benefiting from a portfolio of cancer therapies the company said it was aiming to expand.", "title": "Bristol-Myers Revenue Improves on Cancer-Drug Sales", "url": "http://www.wsj.com/articles/SB10001424052702304632204579340401570440272", "image": {"width": 1200, "identifier": "http://si.wsj.net/img/WSJ_Logo_black_social.gif", "height": 630}, "locale": "en_US", "type": "article"}, "author": "Jonathan D. Rockoff", "article.access": "paid", "page.content.source": "WSJ Online Article", "article.origheadline": "Bristol-Myers Revenue Improves on Cancer-Drug Sales", "article.type": "Earnings", "article.id": "SB10001424052702304632204579340401570440272", "user.exp": "default", "article.updated": "2014-01-24T18:07:00.000Z"}, "_id": "\"57477af36914bd0286fc9b40\"", "article_summary": "Bristol-Myers Squibb Co. reported a better-than-expected 6% rise in fourth-quarter revenue and a 9% rise in adjusted earnings, benefiting from a portfolio of cancer therapies the company said it was aiming to expand.\nBristol said it would be conducting four clinical trials this year of its closely watched experimental cancer treatment nivolumab that could be used to apply for regulatory approval for lung cancer if the drug is shown..."}